1. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002; 82(2): 331–71.
  2. Creutz CE, et al. Protection of the Membrane Permeability Barrier by Annexins. Biochemistry 2012; 51(50): 9966–83.
  3. Draeger A, et al. Plasma membrane repair and cellular damage control: the annexin survival kit. Biochem Pharmacol 2011; 81(6): 703–12.
  5. van Tits L, et al. Ratio of plasma oxidized low-density lipoprotein and annexin A5 positively relates to severity of cardiovascular disease. Atherosclerosis Supplements 2007; 8(1): 85.
  6. Rand JH, et al. Reduction of circulating annexin A5 Levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol 2006; 194(1): 182–8.
  7. Roldan V, et al. Prognostic value of annexin A5-1 C/T polymorphism in a long term follow-up after premature myocardial infarction. Journal of Thrombosis and Haemostasis 2007; 5(4): 862–3.
  8. Roldan V, et al. [Annexin V levels in survivors of early myocardial infarction]. Rev Esp Cardiol 2002; 55(12): 1230–4.
  9. Klement K, et al. Accumulation of annexin A5 at the nuclear envelope is a biomarker of cellular aging. Mechanisms of Ageing and Development 2012; 133(7): 508–22.
  10. Ewing MM, et al. Annexin A5 prevents post-interventional accelerated atherosclerosis development in a dose-dependent fashion in mice. Atherosclerosis 2012; 221(2): 333–40.
  11. Ewing MM, et al. Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. Arterioscler Thromb Vasc Biol 2011; 31(1): 95–101.
  12. Gu CP, et al. Recombinant Human Annexin A5 Can Repair the Disrupted
    Cardiomyocyte Adherens Junctions in Endotoxemia. Shock 2015; 44(1): 83–9.
  13. Liu AQ, et al. Induction of Dendritic Cell-Mediated T-Cell Activation by Modified but Not Native Low-Density Lipoprotein in Humans and Inhibition by Annexin A5 Involvement of Heat Shock Proteins. Arteriosclerosis Thrombosis and Vascular Biology 2015; 35(1): 197–205.
  14. Burgmaier M, et al. AnxA5 reduces plaque inflammation of advanced atherosclerotic lesions in apoE(-/-) mice. Journal of Cellular and Molecular Medicine 2014; 18(10): 2117–24.
  15. Park JH, et al. Annexin A5 Increases Survival in Murine Sepsis Model by Inhibiting HMGB1-Mediated Proinflammation and Coagulation. Molecular Medicine 2016; 22: 424–36.
  16. Arnold P, et al. Recombinant Human Annexin A5 Inhibits Proinflammatory Response and Improves Cardiac Function and Survival in Mice With Endotoxemia. Critical Care Medicine 2014; 42(1): E32–E41.
  17. Kietselaer BL, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med 2004; 350(14): 1472–3.
  18. Kenis H, et al. Annexin A5 Uptake in Ischemic Myocardium: Demonstration of Reversible Phosphatidylserine Externalization and Feasibility of Radionuclide Imaging. Journal of Nuclear Medicine 2010; 51(2): 259–67.
  19. Laufer EM, et al. Annexin A5: an imaging biomarker of cardiovascular risk. Basic Research in Cardiology 2008; 103(2): 95–104.
  20. Boersma HH, et al. Past, present, and future of annexin A5: From protein discovery to clinical applications. Journal of Nuclear Medicine 2005; 46(12): 2035–50.
  21. Miyagi A, et al. High-speed atomic force microscopy shows that annexin V stabilizes membranes on the second timescale. Nature Nanotechnology 2016; 11(9): 783–90.
  22. Oling F, et al. Trimers, dimers of trimers, and trimers of trimers are common building blocks of annexin A5 two-dimensional crystals. Journal of Structural Biology 2001; 133(1): 55–63.
  23. Bouter A, et al. Annexin-A5 assembled into two-dimensional arrays promotes cell membrane repair. Nature Communications 2011; 2.
  24. Insights LEKE. Raising Orphans: How Pharma Can Capture Value while Treating Rare Diseases. L.E.K. Consulting; 2014.
  25. Townsend N, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016; 37(42): 3232–45.
  26. Mozaffarian D, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016; 133(4): e38–360.
  27. Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 2011; 10(5): 365–76.
  28. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013; 339(6116): 166–72.
  29. Bouter A, et al. Review: Annexin-A5 and cell membrane repair. Placenta 2015; 36: S43–S9.
  30. Rand JH, et al. Antiphospholipid antibodies promote coagulation by disrupting the crystal structure of the annexin A5 anticoagulant shield over
  31. Gonzalez-Conejero R, et al. A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. Blood 2002; 100(6): 2081–6.
  32. Cederholm A, et al. Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005; 25(1): 198–203.
  33. Wan M, et al. Oxidized but not native cardiolipin has pro-inflammatory effects, which are inhibited by Annexin A5. Atherosclerosis 2014; 235(2): 592–8.
  34. Domeij H, et al. Annexin A5 inhibits atherogenic and pro-inflammatory effects of lysophosphatidylcholine. Prostaglandins & Other Lipid Mediators 2013; 106: 72–8.
  35. Wautier MP, et al. Red blood cell phosphatidylserine exposure is responsible for increased erythrocyte adhesion to endothelium in central retinal vein occlusion. J Thromb Haemost 2011; 9(5): 1049–55.
  36. Camus SM, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood 2015; 125(24): 3805–14.
  37. Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease. 2015. PR
  38. Liu AQ, et al. Induction of Dendritic Cell-Mediated T Cell Activation by Ldlx and Inhibition by Annexin A5. Journal of Atherosclerosis and Thrombosis 2014; 21: S31–S.
  39. Shelley S. The business of orphan drugs is booming Aug 2015 2015.
  40. Kenis H, et al. Annexin A5: Shifting from a diagnostic towards a therapeutic realm. Cellular and Molecular Life Sciences 2007; 64(22): 2859–62.
  41. Carmeille R, et al. Annexin-A5 promotes membrane resealing in human trophoblasts. Biochimica Et Biophysica Acta-Molecular Cell Research 2015; 1853(9): 2033–44.
  42. Carmeille R, et al. Membrane repair of human skeletal muscle cells requires Annexin-A5. Biochimica Et Biophysica Acta-Molecular Cell Research 2016; 1863(9): 2267–79.
  43. Friedman KA, et al. A Potential Role of Annexin A5 in Inflammatory Bowel Disease. Modern Pathology 2013; 26: 149A–50A.
  44. Schutters K. Annexin A5: Shifting from molecular imaging to therapeutic agent in cardiovascular diseases. Maastricht, Holland: University of Maastricht; 2013.
  45. Cederholm A, Frostegard J. Annexin A5 in cardiovascular disease and systemic lupus erythematosus. Immunobiology 2005; 210(10): 761–8.
  46. Camus SM, et al. Erythrocyte microparticles can induce kidney vaso-occlusions in a murine model of sickle cell disease. Blood 2012; 120(25): 5050–8.
  47. Leader B, et al. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008; 7(1): 21–39.
  48. Belhocine TZ, et al. Tc-99m-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. European Journal of Nuclear Medicine and Molecular Imaging 2015; 42(13): 2083–97.
  49. van Tits LJ, et al. Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochemical and Biophysical Research Communications 2009; 390(1): 161–4.
  50. Bedrood S, et al. Annexin A5 Directly Interacts with Amyloidogenic Proteins and Reduces Their Toxicity. Biochemistry 2009; 48(44): 10568–76.
  51. Bianconi E, et al. An estimation of the number of cells in the human body. Ann Hum Biol 2013; 40(6): 463–71.
  52. Cederholm A, Von Landenberg P, Frostegard J. Decreased annexin A5 binding to endothelium is associated with cardiovascular disease in systemic lupus erythematosus and inhibited by IVIG. Atherosclerosis Supplements 2006; 7(3).
  53. Tzima E, et al. Annexin V relocates to the periphery of activated platelets following thrombin activation: an ultrastructural immunohistochemical approach. Cell Biol Int 1999; 23(9): 629–35.
  54. D’Arceuil H, et al. 99mTc annexin V imaging of neonatal hypoxic brain injury. Stroke 2000; 31(11): 2692–700.
  55. Narula J, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 2001; 7(12): 1347–52.
  56. Belhocine TZ, , et al. (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. Eur J Nucl Med Mol Imaging 2015; 42(13): 2083–97.
  57. Kusters DHM, et al. Molecular Imaging to Identify the Vulnerable Plaque-From Basic Research to Clinical Practice. Molecular Imaging and Biology 2012; 14(5): 523–33.
  58. Chen HH, et al. Cytoprotective nanoparticles by conjugation of a polyhis tagged annexin V to a nanoparticle drug. Nanoscale 2015; 7(6): 2255–9.
  59. CEBR. The economic cost of cardiovascular disease from 2014–2020 in six European economies, 2014.
  60. Research G. Global Cardiovascular Disease Market to 2022-Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth, 2016.
  61. Global Industry Analysis I. Peripheral Arterial Disease (PAD), 2012.
  62. Rogers S, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117(2): 313–9 e1.
  63. Läkemedelsförmånsverket TT-o. Lucentis (ranibizumab) hälsoekonomiskt kunskapsunderlag, 2012.
  64. CANACCORDGenuity, Report 2014.
  65. Research GV. Report, 2016.
  66. CDC. Ebola Outbreak in West Africa-Reported Cases Graphs, 2016.